港股异动 | 春立医疗大涨逾9% 股价创上市以来新高
格隆汇8月28日丨春立医疗(01858.HK)大涨逾9%,报27.8港元,股价已经刷新上市以来新高,成交366万港元,总市值38.46亿港元。春立医疗昨日公布中期业绩,公司实现营业收入人民币3.75亿元(单位下同),同比增长75.93%;归属于公司权益持有人的净利润1.09亿元,同比增长116.62%;每股基本收益0.79元。营业收入增长主要是由于关节假体产品销量的增长及销售网络的扩张所致。受益于陶瓷类关节假体产品等主流高端产品在行业增长迅速,以及加大的销售力度,公司的收入端出现高增长。从行业上,往往下半年的收入要高于上半年,主要是因为上半年过春节,关节手术是择期手术,时间相对比较长;以及下半年一般是麦收的季节,农村病人偏多,夏天不太容易做手术,夏天容易造成感染,下半年一般在10~12月份手术量较多,所以下半年有望延续上半年的增长趋势。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.